

***Topical Cyclosporine A  
Therapy in Children  
With Ocular Rosacea  
and Phlyctenular  
Keratoconjunctivitis***



**Yonca A. Akova, M.D.**

**Bayındır Hospital, Department of Ophthalmology**

**İlkay Kılıç, M.D.**

**Konya Akşehir Hospital , Department of Ophthalmology**

# Financial disclosure

*Dr Akova is a member of speakers bureau for Allergan, Alcon, Bausch Lomb and Thea*

*Dr Kılıç has no financial interests in the subject matter of this poster*

# Purpose

- **To assess the efficacy of topical cyclosporine A (CsA) % 0.05 therapy in children with ocular rosacea and phlyctenular keratoconjunctivitis associated with severe steroid-dependent corneal inflammation and not responding to oral antibiotics**

# Patients Demographics

- 10 children (16 eyes)
- The mean age 10 years (range: 5 - 14 years)
- Female /male ratio (7 girls, 3 boys)
- Cutaneous involvement + in 4 patients



# **Patients and Methods**

- **The disease was previously resistant to**
  - **Lid hygiene and warm compresses**
  - **Oral erythromycin (9 patients)**
  - **Intermittent topical steroids (all patients)**

# Patients and Methods

- **Topical CsA 0.05 % were given four times daily for 6 months or longer**
- **All patients initially received 3x1 topical loteprednol therapy for the first 3-4 weeks**
- **Patients were evaluated with symptoms as well as conjunctival and corneal inflammation**


# Clinical Findings

- All patients had punctate keratopathy and eyelid involvement with meibomitis, blepharitis telangiectasias of the lid margin
- and/ or chalazia
- Corneal vascularization and/or infiltrates were present in 5 eyes



# Therapeutic Response

- All patients showed considerable improvement in ocular symptoms and signs within 6 weeks
  - Lid/conjunctival/corneal inflammation





# Therapeutic Response

- **Inflammation did not recur during CsA therapy with a mean follow-up of  $12 \pm 7$  months**
- **CsA therapy was stopped in all patients after a mean of  $11 \pm 5$  months**
- **No recurrences or intolerance to therapy occurred during follow-up**

# Conclusions

- **Long-term topical CsA 0.05% therapy is safe and effective in children with pediatric ocular rosacea associated with severe steroid-dependent corneal inflammation**
- **It may provide significant relief for children suffering from moderate to severe disease**

**Thank you**

**yoncaakova@yahoo.com**